[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
"Plant-Based Estrogen Has Fewer Side Effects." USA Today, 8
December 97, 1D.
Harry K. Genant, director of the osteoporosis research group
at the University of California, San Francisco, reports that
Estratab, a low-dose form of estrogen derived from soybeans
and yams, helps strengthen bones without the negative side
effects of higher-dose estrogen. His study appears in
_Archives of Internal Medicine_ [which the OPPT Library does
"Estrogen-Mimicking Drug Obtains FDA Approval [National News
Briefs]." New York Times, 11 December 97, A20. "Osteoporosis
Drug [Findings]." Washington Post, 11 December 97, A4. "Lilly's
Osteoporosis Drug is Approved by the FDA, Sparking Marketing
War." Wall Street Journal, 11 December 97, B14.
Raloxifene has received FDA approval and will be marketed by
Eli Lilly under the trade name Evista. The drug does not
protect bone mass quite as well as estrogen but it does not
carry the same risks.